UNSPSC 51262913: Prenalterol hydrochloride

This classification denotes an adrenergic beta-1 receptor agonist C12H19NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6VH18LCQ8, chemically known as phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, hydrochloride, (s)-, but more generally known as prenalterol hydrochloride, which bears US NIH Compound Identifier 43590. European Medicines Agency schedules Prenalterol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04029MIG.

Most nations, for tariff and trade purposes, schedule prenalterol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, PRENALTEROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)NC[C@@H](COC1CCC(CC1)O)O.CL.

UNSPSC 51262913 Prenalterol hydrochloride is a Commodity code whose nominal scope does not align with the recent state and local procurement activity tagged under it. The recent opportunities solicited under this code are naloxone procurement and pharmacy benefit program administration — neither of which is prenalterol hydrochloride. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone units and drug deactivation systems on an annual basis, while the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for state employee and retiree pharmacy benefits. The mismatch between the code's stated product (prenalterol hydrochloride, a cardiac beta-agonist) and the actual procurements (opioid antagonists and pharmacy benefit administration) suggests either a coding error in the jurisdictions' tagging or a data classification issue that obscures the code's actual market activity.

The issuing bodies represent a mix of county health departments and state human services agencies, with no repeat activity within the sample. Geographic activity centers on Florida and Texas. The Seminole County naloxone procurement (IFB, response due July 26, 2023) calls for 1,900 naloxone units and 800 drug deactivation systems delivered quarterly to the Seminole County Community Health Building in Sanford; vendors must include shipping and delivery costs and meet E-Verify and drug-free workplace requirements, with a potential two-year initial term plus one-year renewal option. The Texas HHS RFI (posted April 3, 2026, response due April 3, 2026) seeks vendor capabilities for implementing direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels, with emphasis on self-insured employer and state health plan relationships. No dollar values or formal evaluation criteria are specified in either opportunity.